ABSTRACT
BACKGROUND AND AIMS: The impact of the COVID-19 pandemic on patients with inflammatory bowel disease [IBD] is largely unknown. We characterized the impact of COVID-19 on IBD care by conducting an analysis of US healthcare claims data.
METHODS: We obtained de-identified, open-source health insurance claims data, from January 2019 to December 2020, from the Symphony Health Integrated Dataverse for US adults with IBD and measured the rates, per 1000 patients, of five outcomes: colonoscopies; new biologic or small molecule treatment initiations or treatment switches; new biologic or small molecule treatment initiations or treatment switches in patients who had a colonoscopy within the previous 60 days; IBD-related surgeries; and telehealth consultations.
Read More: https://www.docwirenews.com/abstracts/impact-of-covid-19-on-healthcare-resource-utilization-among-patients-with-inflammatory-bowel-disease-in-the-usa/